Bridgeway Capital Management’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-118,927
| Closed | -$98.1K | – | 1216 |
|
|
2025
Q1 | $98.1K | Hold |
118,927
| – | – | ﹤0.01% | 1039 |
|
|
2024
Q4 | $113K | Hold |
118,927
| – | – | ﹤0.01% | 1096 |
|
|
2024
Q3 | $119K | Sell |
118,927
-80,775
| -40% | -$89.4K | ﹤0.01% | 1138 |
|
|
2024
Q2 | $248K | Sell |
199,702
-115,300
| -37% | -$117K | 0.01% | 1008 |
|
|
2024
Q1 | $410K | Buy |
315,002
+21,327
| +7% | +$24.3K | 0.01% | 975 |
|
|
2023
Q4 | $367K | Buy |
293,675
+34,900
| +13% | +$38.6K | 0.01% | 1016 |
|
|
2023
Q3 | $336K | Buy |
258,775
+180,975
| +233% | +$292K | 0.01% | 988 |
|
|
2023
Q2 | $134K | Sell |
77,800
-70,610
| -48% | -$112K | ﹤0.01% | 1211 |
|
|
2023
Q1 | $217K | Sell |
148,410
-110,200
| -43% | -$211K | 0.01% | 1091 |
|
|
2022
Q4 | $419K | Buy |
258,610
+200,000
| +341% | +$460K | 0.01% | 923 |
|
|
2022
Q3 | $196K | Buy |
58,610
+47,210
| +414% | +$213K | 0.01% | 1145 |
|
|
2022
Q2 | $41K | Buy |
+11,400
| New | +$51.7K | ﹤0.01% | 1293 |
|
Bridgeway Capital Management's KRON Position: Q2 2025 in Review
Bridgeway Capital Management sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 118,927 shares — an estimated $98.1K sold.
Bridgeway Capital Management first reported a position in KRON in Q2 2022 and held it in 12 quarters. The position peaked at $419K in Q4 2022. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Bridgeway Capital Management reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Bridgeway Capital Management sold 118,927 Kronos Bio shares in Q2 2025, an estimated $98.1K.
- Bridgeway Capital Management first reported a position in Kronos Bio in Q2 2022 and held it in 12 quarters.
- Bridgeway Capital Management's Kronos Bio position peaked at $419K in Q4 2022.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Bridgeway Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.